# US 2026/0159866 A1 · Methods for the chemoenzymatic synthesis of low molecular weight heparin from low molecular weight heparosan

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0159866 A1
- Document ID: US20260159866A1
- Status: Published application
- Kind: A1
- Application number: 18/707,500
- Filed: 2022-11-04
- Published: 2026-06-11
- Earliest claimed: 2021-11-05
- Assignees: Rensselaer Polytechnic Institute; Otsuka Pharmaceutical Factory, Inc.
- Applicants: Rensselaer Polytechnic Institute; Otsuka Pharmaceutical Factory, Inc.
- Inventors: Robert John LINHARDT; Jonathan Seth DORDICK; Yanlei YU; Li FU; Peng HE; Ke XIA; Sony VARGHESE; Fuming ZHANG
- Web page: https://patentgrep.com/patent/US20260159866A1

## CPC

- C08B 37/0075: {Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof}
- C12P 19/04: Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
- C08B 37/0078: {Degradation products}
- C08L 5/10: Heparin; Derivatives thereof
- C12N 9/13: {transferring sulfur containing groups (2.8)}
- C12N 9/90: Isomerases (5.)
- C12P 19/24: produced by the action of an isomerase, e.g. fructose
- C12Y 208/02: Sulfotransferases (2.8.2)
- C12Y 501/03: acting on carbohydrates and derivatives (5.1.3)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Low molecular weight heparin (LMWH) suitable for equivalent use to USP enoxaparin sodium is prepared from a starting material isolated from engineered E. coli K5 capsular polysaccharide, e.g., E. coli K5 heparosan. The E. Coli CPS is treated with acids to remove 3-deoxy-D-manno oct-2-ulosonic acid (Kdo) residues, and further hydrolyzed via alkali treatment to form low molecular weight N-sulfo, N-acetyl heparosan (LMW-NSNAH) having molecular weight and N-acetylation comparable to enoxaparin. The LMW-NSNAH is converted to LMWH via a series of enzymatic modifications by C5-epimerase, 2-O-, 6-O-, and 3-O-sulfotransferases. Compositions including the LMWH are prepared without the use of porcine-derived heparin, and thus benefit from better source material availability, better control of manufacturing processes, reduced concerns about contamination, adulteration or animal virus, or impurities. Further, the LMWH product is demonstrated to be structurally and functionally comparable traditional pharmaceutical LMWHs.

## Claims

### Claim 1

A method of making low molecular weight heparin (LMWH), comprising:
providing an amount of heparosan;
contacting the heparosan with one or more acids to form acid-treated heparosan;
converting the acid-treated heparosan by depolymerization and de-N-acetylation thereof to form low molecular weight N-sulfo, N-acetyl heparosan (LMW-NSNAH); and
enzymatically converting the LMW-NSNAH to LMWH,
wherein the heparosan is an E. coli capsular polysaccharide.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the heparosan is synthesized via an engineered strain of E. coli K5.

### Claim 3 (depends on 1)

The method according to claim 1, wherein contacting the heparosan with one or more acids to form acid-treated heparosan includes:
removing 3-deoxy-D-manno oct-2-ulosonic acid (Kdo) residues from the heparosan via acid hydrolysis.

### Claim 4 (depends on 1)

The method according to claim 1, wherein converting the acid-treated heparosan to LMW-NSNAH includes hydrolysis of the acid-treated heparosan via:
treatment of the acid-treated heparosan with one or more bases;
treatment of the acid-treated heparosan with one or more additional acids;
contacting the acid-treated heparosan with one or more enzymes; or
combinations thereof.

### Claim 5 (depends on 1)

The method according to claim 1, wherein converting the acid-treated heparosan by depolymerization and de-N-acetylation thereof to LMW-NSNAH further includes:
re-acetylating the acid-treated heparosan after de-N-acetylation thereof; and
N-sulfating the acid-treated heparosan to obtain LMW-NSNAH.

### Claim 6 (depends on 5)

The method according to claim 5, wherein:
re-acetylating the acid-treated heparosan after de-N-acetylation thereof includes:
contacting the acid-treated heparosan with acetic anhydride; and
N-sulfating the acid-treated heparosan to obtain LMW-NSNAH includes:
contacting the acid-treated heparosan with trimethylamine sulfur trioxide, pyridine sulfur trioxide, or combination thereof.

### Claim 7 (depends on 5)

The method according to claim 5, wherein re-acetylating the acid-treated heparosan after de-N-acetylation thereof includes:
contacting the acid-treated heparosan with about 53 μM/L acetic anhydride.

### Claim 8 (depends on 5)

The method according to claim 5, wherein N-sulfating the acid-treated heparosan to obtain LMW-NSNAH further comprises:
contacting the acid-treated heparosan with about 76 mM/L trimethylamine sulfur trioxide.

### Claim 9 (depends on 1)

The method according to claim 1, wherein enzymatically converting the LMW-NSNAH to LMWH further comprises:
contacting the LMW-NSNAH with C5-Epi and 2-OST to form N-sulfo, N-acetyl, 2-O-sulfo IdoA-including heparosan (NSNA2SH).

### Claim 10 (depends on 9)

The method according to claim 9, wherein enzymatically converting the LMW-NSNAH to LMWH further comprises:
contacting the NSNA2SH with 6-O-sulfotransferase-3, 6-O-sulfotransferase-1, or combinations thereof to form N-sulfo, N-acetyl, 2-O-sulfo, 6-O-sulfo IdoA-including heparosan (NSNA2S6SH).

### Claim 11 (depends on 10)

The method according to claim 10, wherein enzymatically converting the LMW-NSNAH to LMWH further comprises:
contacting the NSNA2S6SH with 3-O-sulfotransferase-1 to form LMWH.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the LMW-NSNAH has a molecular weight between about 3,800 and about 4,500 daltons.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the LMW-NSNAH includes between about 10% to about 15% N-acetyl groups.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the LMWH is a heterogeneous, polydisperse form of enoxaparin with an anti-factor Xa between about 90 and about 125 IU/mg.

### Claim 15

An intermediate low molecular weight N-sulfo, N-acetyl heparosan (LMW-NSNAH), the LMW-NSNAH being produced by a method including:
providing an amount of heparosan, wherein the heparosan is an E. coli capsular polysaccharide;
contacting the heparosan with one or more acids to remove 3-deoxy-D-manno oct-2-ulosonic acid (Kdo) residues from the heparosan via hydrolysis to form acid-treated heparosan; and
converting the acid-treated heparosan by depolymerization and de-N-acetylation thereof to form LMW-NSNAH;
wherein the LMW-NSNAH has a molecular weight and a ratio of N-sulfo groups and N-acetyl groups such that enzymatic treatment thereof with a C5-epimerase and at least one sulfotransferase yields a final product with molecular weight and chemical properties consistent with animal-derived enoxaparin.

### Claim 16 (depends on 15)

The intermediate LMW-NSNAH according to claim 15, wherein the LMW-NSNAH has a molecular weight between about 3,800 and about 4,500 daltons.

### Claim 17 (depends on 15)

The intermediate LMW-NSNAH according to claim 15, wherein the LMW-NSNAH includes between about 10% to about 15% N-acetyl groups.

### Claim 18 (depends on 15)

The intermediate LMW-NSNAH according to claim 15, wherein converting the acid-treated heparosan to LMW-NSNAH includes hydrolysis via:
treatment of the acid-treated heparosan with one or more bases;
treatment of the acid-treated heparosan with one or more additional acids;
contacting the acid-treated heparosan with one or more enzymes; or
combinations thereof.

### Claim 19 (depends on 15)

The intermediate LMW-NSNAH according to claim 15, wherein converting the acid-treated heparosan by depolymerization and de-N-acetylation thereof to LMW-NSNAH further includes:
adding the acid-treated heparosan to a reaction medium including methanol, anhydrous sodium carbonate, and about 53 μM/L acetic anhydride to form re-acetylated heparosan; and
adding the re-acetylated heparosan to a reaction medium including anhydrous sodium carbonate and about 76 mM/L trimethylamine sulfur trioxide to obtain LMW-NSNAH.

### Claim 20

A composition including a low molecular weight heparin (LMWH), wherein the LMWH is prepared via enzymatic conversion of low molecular weight N-sulfo, N-acetyl heparosan (LMW-NSNAH) prepared from E. coli capsular polysaccharide.
